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Vif multimerizationfactor (Vif) is required during viral replication to inactivate the host cell anti-viral
factor, APOBEC3G (A3G). Vif binds A3G and a Cullin5-ElonginBC E3 ubiquitin ligase complex which results in
the proteasomal degradation of A3G. The Vif PPLP motif (amino acids 161–164) is essential for normal Vif
function because mutations in this motif reduce the infectivity of virions produced in T-cells. In this report,
we demonstrate that mutation of the Vif PPLP motif reduces Vif binding to A3G without affecting its
interaction with ElonginC and Cullin5. We demonstrate that the failure of the Vif mutant to bind A3G
resulted in A3G incorporation into assembling virions with loss of viral infectivity.
© 2008 Elsevier Inc. All rights reserved.IntroductionHIV-1virion infectivity factor (Vif) functionsduring theviral life cycle
to inactivate the host cytidine deaminase, APOBEC3G (A3G) (Sheehy
et al., 2002). In the absence of Vif, A3G is efﬁciently incorporated into
progeny virions. Following infection of target cells, A3G catalyzes the
deamination of deoxycytidine residues in the viral cDNA minus strand
during reverse transcriptionwhich leads to inhibition of viral replication
(Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al., 2003). Vif
prevents A3G incorporation into assembling virions by inducing its
degradation through the ubiquitin–proteasome pathway (Conticello
et al., 2003; Marin et al., 2003; Mehle et al., 2004b; Sheehy et al., 2003;
Stopak et al., 2003; Yu et al., 2003).
Deletion of the highly conserved Vif PPLP motif (amino acids 161–
164) reduces the infectivity of progeny virions produced in non-
permissive T-cells (Yang et al., 2001). Mutation of this motif also
eliminates Vif–Vif interaction in vitro (Yang et al., 2003, 2001), and it
has been suggested that Vif multimerizationmay be necessary for A3G
binding (Miller et al., 2007). However, this region also has been
identiﬁed as part of a novel “SOCS-box”motif implicated in Vif binding
to ElonginC (Mehle et al., 2004a; Yu et al., 2004) and to be involved in
Vif interaction with the cellular Hck tyrosine kinase (Hassaine et al.,
2001; Yang et al., 2003). Treatment of cells with PPLP motif peptides
that disrupt Vif multimerization in vitro reduce viral replication (Yang
et al., 2003), as well as increase virion incorporation of A3G and reduce
the infectivity of those virions (Miller et al., 2007). However, theonahue).
l rights reserved.mechanism underlying this requirement for wild type amino acids at
Vif residues 161–164 was not investigated in these studies. In this
report, we present data that adds to our understanding of the
molecular mechanism of the requirement for an intact Vif PPLP motif
for infectious virus production in non-permissive cells. We demon-
strate that mutation of the Vif PPLP motif impaired the ability of Vif to
bind A3G, and did not affect ElonginC and Cullin5 binding. As a
consequence, the Vif mutant failed to induce A3G degradation and did
not prevent A3G incorporation into virions.
Results
The Vif PPLP motif is necessary for A3G binding and degradation
To investigate whether an intact Vif PPLP motif (residues 161–164)
is necessary for the functional interaction with A3G in vivo, we
introduced substitution mutations in Vif which replaced PPL residues
161–163 with alanine residues [Vif(A161AA)]. We determined the
effect of this mutation on the induction of A3G degradation by com-
paring the effect in 293T cells co-transfected with plasmids direct-
ing the expression of HA-tagged A3G and either wild type Vif or Vif
(A161AA). Cell lysates were prepared 24h after transfection and A3G
and Vif protein levels were analyzed by Western blotting. The results
of this analysis showed that mutation of the PPLP motif impaired the
ability of Vif to induce the degradation of A3G (Fig. 1A). To investigate
themechanism of this defect, the ability of Vif(A161AA) to interact with
A3G in vivo was determined by co-immunoprecipitation of A3G-Vif
complexes with anti-HA antibody beads. The results of this analysis
demonstrated that the binding of Vif(A161AA) to A3G-HAwas reduced
compared to wild type Vif binding (Fig. 1A). To conﬁrm this result,
Fig. 1. The Vif PPLP motif is necessary for A3G binding and degradation. (A) HEK293T
cells were co-transfected with plasmids expressing HA-tagged A3G (pA3G-HA) and
either wild type Vif (pHVif) or PPL mutant Vif [pHVif(A161AA)] as indicated. Cell lysates
were prepared 24 h after transfection and the levels of A3G and Vif determined by
Western blotting (WB). A3G binding to wild type Vif or PPL mutant Vif was determined
by co-immunoprecipitation of protein complexes from cell lysates using anti-HA
antibody beads. (B) HEK293T cells were co-transfected with plasmids expressing A3G
(pA3G) and HA-tagged Vif (pHVif-HA) or PPL mutant Vif [pHVif(A161AA)-HA] as
indicated. Cell lysates were prepared 24 h after transfection and A3G binding to wild
type Vif or PPL mutant Vif was determined by co-immunoprecipitation of protein
complexes using anti-HA antibody beads. Co-immunoprecipitated proteins were
identiﬁed by Western blotting (WB) using the indicated antibodies as described in
Materials and methods.
Fig. 2. The Vif PPL mutant binds ElonginC and Cullin5. HEK293T cells were co-
transfected with plasmids expressing HA-tagged ElonginC (pEloC-HA), Myc-tagged
Cullin5 (pCul5-Myc), and either wild type Vif (pHVif) or PPL mutant Vif [pHVif(A161AA)]
as indicated, and cell lysates were prepared 24 h after transfection. Binding of wild type
Vif and PPL mutant Vif to ElonginC (A) and Cullin5 (B) was assessed by co-
immunoprecipitation of protein complexes from cell lysates using either anti-HA
antibody or anti-c-myc beads as indicated. Co-immunoprecipitated proteins were
identiﬁed by Western blotting (WB) using the indicated antibodies as described in
Materials and methods.
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and either HA-tagged Vif wild type or PPL mutant and A3G-Vif
complexes were immunoprecipitated using anti-HA antibody beads.
The results of this analysis demonstrated A3G association with HA-
tagged wild type Vif and reduced interaction with the HA-tagged Vif
PPL mutant (Fig. 1B). In sum, these results demonstrated that an intact
Vif PPLP motif is necessary for A3G binding and degradation.
Vif(A161AA) is not defective in binding to ElonginC and Cullin5
It has been demonstrated that Vif interacts directly with ElonginC
and Cullin5 in the assembly of an E3 ubiquitin ligase complex that is
necessary for proteasomal degradation of A3G (Mehle et al., 2006;
Xiao et al., 2006; Yu et al., 2004). Because of the requirement for E3
ubiquitin ligase in Vif induced A3G degradation, we sought to
determine the effect of the PPL mutation on ElonginC and Cullin5
binding. 293T cells were co-transfected with plasmids encoding HA-
tagged ElonginC or Myc-tagged Cullin5 and either wild type Vif or Vif
(A161AA). Cell lysates were prepared 24h after transfection and protein
complexes were immunoprecipitated either with anti-HA or anti-myc
antibody beads. Co-immunoprecipitated proteins were identiﬁed by
Western blotting (Fig. 2). The results of this analysis showed that Vif
(A161AA) binding to ElonginC (Fig. 2A) and Cullin5 (Fig. 2B) was
comparable to wild type Vif binding to these proteins. This result
demonstrated that Vif recruitment and assembly of an E3 ubiquitin
ligase complex does not require an intact Vif PPLP motif.Mutation of the Vif PPLP motif affects the infectivity of virus produced in
A3G expressing cells
We demonstrated that mutation of the Vif PPLP motif impaired Vif
induction of A3G degradation in transient transfection assays (Fig. 1A).
To conﬁrm that the failure of the mutant Vif to induce A3G
degradation resulted in the predicted reduction in viral infectivity,
we measured the competency of the Vif(A161AA) mutant to rescue the
infectivity of a vif-deleted virus. HEK293-APOBEC3G-HA cells, stably
expressing HA-tagged A3G, were co-transfected with pNL4-3(Δvif)
provirus and either pcDNA3-HVif or pcDNA3-HVif(A161AA). Culture
supernatants were collected 48h after transfection and viral infectivity
was determined (Fig. 3A). The results showed that complementation
of pNL4-3(Δvif) by wild type Vif resulted in a level of infectivity
equivalent to virus produced from cells transfected with wild type
pNL4-3 provirus. However, in comparison to wild type Vif, the Vif
(A161AA) mutant was unable to complement the vif-deleted provirus
and infectivity was essentially equivalent to pNL4-3(Δvif) alone.
To correlate the observed infectivity data with the level of virion
incorporation of A3G, virus was collected by centrifugation of culture
supernatants through a 20% sucrose cushion and A3G content was
analyzed by Western blotting. This analysis showed that Vif(A161AA)
was defective in blocking the incorporation of A3G into virions
(Fig. 3B). The level of A3G incorporation was similar to that observed
in the vif-deleted provirus alone. A low, but equivalent, level of A3G
was also detected in virions produced by both wild type Vif-
complemented pNL4-3(Δvif) and Vif-positive pNL4-3 provirus. Finally,
low levels of Vif were detected in virions produced by wild type Vif-
and Vif(A161AA)-complemented pNL4-3(Δvif), as well as wild type Vif-
positive pNL4-3 provirus. It has been demonstrated that incorporation
Fig. 3. Mutation of the Vif PPLP motif affects the infectivity of virus produced in A3G
expressing cells. HEK293-APOBEC3G-HA cells were co-transfected with proviral
plasmid pNL4-3(Δvif) and plasmids expressing either wild type Vif (pHVif) or PPL
mutant Vif [pHVif(A161AA)]. Cells were also co-transfected with proviral plasmid pNL4-
3 or pNL4-3(Δvif) plus empty vector, pcDNA3.1(−). (A) Viral infectivity of culture
supernatants 48 h post-transfectionwas determined using the TZM-bl indicator cell line
as described in Materials and methods. Shown are Relative Light Units (RLU) plus
standard deviation of triplicate determinations normalized to the viral p24 levels
measured in culture supernatants. (B) Analysis of A3G and Vif levels in viral and cell
lysates by Western blotting (WB). The antibodies used to detect A3G, Vif, p24 and β-
actin are described in Materials and methods.
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(Khan et al., 2001). Viral incorporation of Vif(A161AA) at levels
comparable to wild type Vif indicated that mutation of the Vif PPLP
motif did not alter the RNA binding activity of Vif. Western blot
analysis of cell lysates of the co-transfected cells demonstrated similar
levels of expression of wild type Vif and Vif(A161AA), as well as A3G-
HA. In these cells, A3G-HA is constitutively expressed at a high level,
which may explainwhy the levels of this protein appear unaffected by
wild type Vif in thisWestern blot compared to the results presented in
Fig. 1A.
Discussion
In HIV-1 infected cells, Vif counteracts the activity of the host
restriction factor A3G by inducing its proteasomal degradation. In this
process, Vif functions as the substrate recognition subunit for an E3
ubiquitin ligase complex comprised of Cullin5, ElonginBC, and RbxI
(Kobayashi et al., 2005; Mehle et al., 2004a; Yu et al., 2003, 2004). Vif
binds A3G and assembles the E3 ubiquitin ligase complex through
direct interaction with ElonginC and Cullin5. In addition, the pro-
duction of infectious virions in non-permissive cells has been shown
to require an intact PPLP motif which is implicated in mediating Vif
multimerization in vitro. However, the molecular mechanism of the
requirement for an intact PPLP motif in Vif has not yet been described.
In this report, we provide a mechanistic basis for this requirement by
demonstrating that mutation of the PPLP motif impaired the ability of
Vif to bind A3G, but not to assemble an E3 ligase complex. As a
consequence, the Vif mutant failed to induce A3G degradation
and prevent A3G incorporation into virions resulting in loss of viral
infectivity.
The majority of published reports have suggested that the binding
site for A3G is located in the amino-terminal region of Vif and two
recent studies presented evidence of the direct involvement ofresidues Y40RHHY in A3G binding (Mehle et al., 2007; Russell and
Pathak, 2007). In themutant we constructed, Vif PPL residues 161–163
were changed to alanine residues [Vif(A161AA)] which resulted in a
reduction in A3G binding capacity. The loss of A3G binding by the Vif
(A161AA) mutant probably was not caused by disruption of the native
Vif structure as binding of ElonginC, Cullin5 and HIV-1 genomic RNA
were all unaffected. The Vif binding site for HIV-1 genomic RNA maps
between amino-terminal residues 1–64 (Zhang et al., 2000) and
overlaps the Vif sequences recently demonstrated to bind A3G (Mehle
et al., 2007; Russell and Pathak, 2007), further supporting the
suggestion that the native structure of this region was unaffected by
the carboxyl-terminal substitution mutations.
The results presented in this report suggest that Vif multi-
merization or post-translational modiﬁcation involving the Vif PPLP
motif is required for A3G binding, but not for binding to ElonginC
and Cullin5. This indicates that the structural determinants of Vif
recognition of A3G may be fundamentally different from those in-
volved in Vif interaction with ElonginC and Cullin5. The potential
importance of Vif multimerization, for which the PPLP motif has been
demonstrated to be necessary in vitro and not yet in vivo, is supported
by a recent study that probed Vif structure using chemical cross-
linking, proteolysis and mass spectrometry of Vif monomers, di-
mers and trimers (Auclair et al., 2007). The results of that study
demonstrated that Vif undergoes substantial changes in tertiary
structure following protein multimerization in vitro. The changes in
Vif tertiary structure as a consequence of protein multimerization,
as well as the contribution of quaternary structure, may result in
the formation and/or stabilization of an A3G binding site that is ab-
sent from the Vif monomeric structure. However, our data is also
consistent with the Vif PPLP mutations abrogating a different struc-
tural or functional role of that motif, including the possibility that it
contributes to post-translational modiﬁcation of Vif needed for A3G
binding.
Vif binding to ElonginC and Cullin5 was not affected by mutation
of the PPLP motif in the current study. The binding sites for these
proteins are well-deﬁned and located in the carboxyl-terminal re-
gion of Vif. The highly conserved Vif S144LQYLAAL and downstream
L163PxxxxL amino acid sequences share homology with the SOCS-box
motifs of several cellular proteins that bind ElonginC (Kamura et al.,
1998; Zhang et al., 1999). Mutational analysis has demonstrated the
central role of the Vif S144LQYLAAL motif in binding ElonginC in
the adaptor complex comprised of ElonginBC (Mehle et al., 2004a; Yu
et al., 2004). This sequence is predicted to adopt an alpha helical
structure, binding ElonginC through hydrophobic interactions. The
downstream L163PxxxxL motif may not be necessary for Vif–ElonginC
complex formation (Mehle et al., 2004a), although another report
suggested that potential hydrophobic contacts with L163 and L169
may help stabilize ElonginC binding (Yu et al., 2004). In that report,
substitution of L163 with serine within the PPLP motif impaired Vif
binding to ElonginC but substitution of L163 with alanine had a lesser
negative effect (Yu et al., 2004). This latter observation is consistent
with the data presented in the current study demonstrating that
the PPL161–163AAA mutation did not affect Vif binding to ElonginC.
The binding site for Cullin5 involves a zinc stabilized HCCH motif
encompassing Vif residues H108–H139 (Luo et al., 2005; Mehle et al.,
2006; Xiao et al., 2006). This region is predicted to form a novel zinc
ﬁnger domain containing a predicted alpha helix which contacts
Cullin5 through hydrophobic interactions. The Vif binding sites for
ElonginC and Cullin5 are contiguous and the secondary structure of
the interacting surfaces appears similar. Our results showing that the
Vif(A161AA) mutant retained binding to both ElonginC and Cullin5
suggests that the Vif monomer possesses the necessary secondary and
tertiary structure to bind the E3 ubiquitin ligase complex. Validation of
these conclusions awaits the determination of the three-dimensional
crystal structures of Vif and the Vif-A3G and Vif–ElonginBC–Cullin5
complexes.
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Plasmids and cell lines
A full length infectious HIV-1 clone, pNL4-3 (Adachi et al., 1986),
and isogenic vif-deleted clone, pNL4-3(Δvif), were obtained from Dr.
Chris Aiken. The Vif expression plasmid pcDNA-HVif was obtained
through the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH from Dr. Stephan Bour and Dr. Klaus
Strebel. The vif mutant plasmid pcDNA-HVif(A161AA)], encoding Vif
(PPL161–163AAA), was constructed from pcDNA-HVif by site directed
mutagenesis using the Quick Change™ Site-directed Mutagenesis Kit
(Stratagene) as described by the manufacturer. Plasmids pCul5-Myc
(Yu et al., 2003) and pEloC-HA (Yu et al., 2004) were obtained from Dr.
Bindong Liu. A plasmid encoding A3G with a single carboxyl-terminal
HA tag was constructed by PCR from pCEM-15 (Sheehy et al., 2002)
using appropriate primers and insertion in the NotI and HindIII sites of
pcDNA3.1(−). HEK293-APOBEC3G-HA (Yu et al., 2003) cells were
obtained through the NIH AIDS Research and Reference Reagent
Program from Dr. Xiao-Fang Yu. TZM-bl indicator cells were obtained
through the NIH AIDS Research and Reference Reagent Program from
Dr. John C. Kappes, Dr. XiaoyunWu and Tranzyme, Inc. The TZM-bl cell
line, a genetically engineered HeLa cell clone expressing CD4, CXCR4,
CCR5 and Tat-responsive ﬁreﬂy luciferase and Escherichia coli ß-
galactosidase under the control of an HIV-1 long terminal repeat.
Antibodies
HIV-1HXB2 Vif antiserum and anti-ApoC17 antibody, which recog-
nizes the 17 carboxyl-terminal residues of human APOBEC3G, were
obtained through the NIH AIDS Research and Reference Reagent
Program from Dr. Dana Gabuzda and Dr. Klaus Strebel, respectively.
Rabbit anti-human c-myc and anti-hemagglutinin (HA tag) antibodies
were from USBiological. Anti-HA (clone 3F10) afﬁnitymatrix was from
Roche and anti-c-myc (clone 9E10) Sepharose-4B beads were from the
Vanderbilt University Antibody Core. Anti-β-actin monoclonal anti-
body (clone AC-74) was from Sigma. Anti-p24 monoclonal antibody
183-H12-5C was from Vanderbilt-Meharry Center for AIDS Research
Virology Core.
Immunoprecipitation and Western blot analysis
HEK293T cells were plated at a density of 400,000 cells/well in a 6-
well culture plate 24 h prior to transfection. Cells were co-transfected
with pcDNA-HVif, pcDNA-HVif(A161AA), pcDNA-A3G(HA), pCul5-Myc,
and pEloC-HA plasmid DNA as indicated in individual ﬁgure legends
using linear polyethylenimine (PEI; 25 kDa; Polysciences, Inc.) essen-
tially as described before (Durocher et al., 2002). Cells were harvested
24h after transfection in ice-cold PBS and lysed in250 μl of lysis/IPbuffer
[50mMHEPES (pH 7.4),150mMNaCl,1mMNa2EDTA, 0.2%NP-40 (v/v),
0.1 mM PMSF and complete mini protease inhibitor cocktail without
Na2EDTA (Roche)]. Cell lysates were incubated at 4 °C for 30 min with
constantmixing and then centrifuged at 10,000 ×g for 5min at 4 °C. The
supernatant fraction was removed and mixed with 10 μl (packed bead
volume) of either mouse HA antibody conjugated agarose beads or
mouse c-myc antibody conjugated Sepharose 4B beads. Samples were
incubated at 4 °C for 18 h with constant mixing. Antibody beads were
collected bycentrifugation at 500 ×g andwashed successivelywith lysis/
IP buffer and lysis/IP buffer with 500 mM NaCl. Captured protein was
then eluted from the antibody beads by incubation in SDS-protein
sample buffer [50 mM Tris–HCl (pH 6.8), 2 mMNa2EDTA, 2% SDS, 2% 2-
mercaptoethanol, 10% glycerol, 0.05% bromophenol blue] at 100 °C for
5 min and then separated by SDS-PAGE. Proteins were transferred to an
Immobilon-P membrane (Millipore) and processed for Western blot
analysis using speciﬁc antibodies, as indicated in ﬁgure legends, and
chemiluminescent detection.Vif complementation assay
HEK293-APOBEC3G-HA cells were plated at a density of 3×106
cells/100mm culture dish 24 h prior to transfection. Using the calcium
phosphate precipitationmethod (Chen andOkayama,1987), cellswere
co-transfected with 15 μg of pNL4-3(Δvif) and either 5 μg of pcDNA-
HVif or 5 μg of pcDNA-HVif(A161AA) to produce vif complemented
virus. Cells were also co-transfected with 15 μg of pNL4-3 or pNL4-3
(Δvif) and 5 μg of pcDNA3.1(−) as positive and negative controls,
respectively. Culture supernatants were collected 48 h after transfec-
tion and passed through a 0.45 μm ﬁlter to remove cellular debris. Viral
particle content in culture supernatants was quantiﬁed by a capsid-
speciﬁc (p24) ELISA as described (Wehrly and Chesebro, 1997). Virions
were concentrated by centrifugation of culture supernatants through a
20% sucrose cushion at 125,000 ×g for 45min and normalized for their
p24 content with viral lysis buffer [50 mM Tris (pH 8.0), 40 mM KCl,
50 mM NaCl, 5 mMNa2EDTA, 10 mMDTT and 0.1% (v/v) Triton X-100].
Transfected cells were lysed in 1 ml of lysis buffer [50 mM HEPES (pH
7.4),150mMNaCl,1mMNa2EDTA, 0.5% NP-40 (v/v), 0.1mM PMSF and
complete mini protease inhibitor cocktail without Na2EDTA (Roche)].
Cell lysates were incubated at 4 °C for 30 min with constant mixing,
centrifuged at 10,000 ×g for 5 min (4 °C) and the supernatant fraction
removed for Western blot analysis as described above.
Viral infectivity assay
TZM-bl indicator cells were plated at a density of 15,000 cells/well
in a 96 well culture plate 24 h prior to infection and incubated at 37 °C
(5% CO2). The day of infection, the culture medium was removed and
the cells inoculated in triplicate with 200 μl of 5-fold serial dilutions of
viral supernatants in culture medium containing 20 μg/ml DEAE dex-
tran and incubated at 37 °C (5% CO2). After 60 h incubation, 100 μl of
culture supernatant was removed from each well and replaced with
100 μl of Bright-Glo Luciferase Assay substrate (Promega). Following
2 min incubation at room temperature, 100 μl of each cell lysate was
transferred to a 96 well OptiPlate 96 (Perkin Elmer) and luminescence
was measured in a TopCount scintillation counter (Packard/Perkin
Elmer). Results are reported as Relative Light Units (RLU) recorded in
the linear range of viral supernatant dilutions.
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